MedTrace Logo

Extended-Release RANCAD in the Patients With Stable Angina Pectoris

NCT02294942 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2017-04-28

No results posted yet for this study

Summary

A double-blind, randomized, placebo-controlled, parallel study to evaluate the effects of add-on RANCAD on exercise tolerance and angina frequency in patients with stable angina pectoris.

Conditions

  • Stable Angina Pectoris

Interventions

DRUG

RANCAD

Extended-Release RANCAD

Sponsors & Collaborators

  • TSH Biopharm Corporation Limited

    lead INDUSTRY

Principal Investigators

  • Juey-Jen Hwang, M.D., Ph.D., · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02294942 on ClinicalTrials.gov